Moderna plunges on downgrade amid vaccine headwinds
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Equities rebound to close higher as surging Treasury yields recede
- Fed’s Jefferson sees no urgency for another rate increase
- Oil jumps 4% on reports China halts fuel exports, US troops head to Middle East
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Anthropic targets mid-November for public debut - report
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
Deutsche Bank Upgrades Moderna (MRNA) to Hold, 'a more troublesome Winter’s Tale, but up to Hold'
August 6, 2024 4:18 PM EDTDeutsche Bank analyst Emmanuel Papadakis upgraded Moderna (NASDAQ: MRNA) from Sell to Hold with a price target of $80.00 (from $85.00).
The analyst comments "We update after Q2s difficult print (Moderna: Q2 first take. Set to be pursued by many bears?*: winter reckoning arrives early (01/08/24)), which delivered the triple-blow of downgraded revenue, reduced gross margin and maintained... More
